ATR vs CRNX
AptarGroup vs Crinetics Pharmaceuticals, Inc. — AI-powered side-by-side comparison
VS
CRNX
Crinetics Pharmaceuticals, Inc.
65
Buy
| Metric | ATR | CRNX |
|---|
| AI Score |
69
|
65
|
| Price |
$134.62
|
$84.35
|
| P/E Ratio |
24.06×
|
-16.70×
|
| ROE |
14.7%
|
-46.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
28.3%
|
99.2%
|
| Debt / Equity |
0.54×
|
0.00×
|
| Dividend Yield |
1.4%
|
0.0%
|
| RSI (14) |
48.2
|
89.2
|
| Beta |
0.382
|
0.1302
|
| Expected Upside |
+1.6%
|
—
|
AI Committee View
Current Innellis committee reasoning for ATR versus CRNX.
ATR leads by 4 points.
ATR scores 69/100 (Buy) versus CRNX at 65/100 (Buy).
ATR Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is macd histogram negative -- bearish momentum. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
CRNX Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 2928.4% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price-to-book of 4.5x prices in significant intangible value — Value
- ROE of only -44.2% -- cheap may mean cheap for a reason — Value
- RSI at 89 is in overbought territory — Technical